MediWound develops and commercializes topical enzymatic therapeutics that selectively remove damaged or non-viable tissue while preserving healthy tissue, offering non-surgical alternatives to traditional debridement methods. The company's flagship product, NexoBrid, is approved for treating deep burns in over 45 countries and generates revenue through an exclusive U.S. license with Vericel (generating tiered royalties and milestone payments), direct sales in Europe, and distribution partnerships globally; the company also receives development and procurement funding from the U.S. Biomedical Advanced Research and Development Authority. A pipeline candidate, EscharEx, targets chronic hard-to-heal wounds including venous leg ulcers and diabetic foot ulcers, with potential peak sales estimated at approximately $831 million, supported through partnerships with major wound care companies. MediWound manufactures its products in an in-house cGMP-certified facility in Israel and relies on exclusive supply agreements for key raw materials.